Key Objective To document the long-term outcome of a cohort of children and teenagers diagnosed with widespread, multifocal, ALK-positive inflammatory myofibroblastic tumors (AP-IMTs) treated in a crizotinib compassionate use access program. This evidence concerns the gene ALK and inflammatory myofibroblastic tumor.